LFSC
F/m Emerald Life Sciences Innovation ETF·NASDAQ
--
--(--)
--
--(--)
Key Stats
Assets Under Management
98.64MUSD
Fund Flows (1Y)
11.12MUSD
Dividend Yield
--
Discount/Premium to NAV
-0.01%
Shares Outstanding
2.50M
Expense Ratio
0.79%
About F/m Emerald Life Sciences Innovation ETF
Issuer
F/m Investments LLC
Brand
F/m
Home Page
Inception Date
Oct 30, 2024
Structure
Open-Ended Fund
Index Tracked
--
Management Style
Active
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
F/m Investments LLC
Distributor
Quasar Distributors LLC
LFSC seeks to invest in innovative life sciences companies that are expected to create value and long-term growth. The actively managed fund relies on a specialized and experienced team to research complex life sciences companies. It invests in US equity securities identified to have growth potential that meet the criteria of technological advancement, market disruption, or artificial intelligence. The broad life science field includes biotechnology, pharmaceutical, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection employs an extensive 10-step research process that includes reviews of publicly available and third-party information, peer reviews, financial and valuation models, internal research, surveys, as well as interviews and contact with management, industry and medical professionals, supply chain, and collaboration within the investment team. The fund may invest up to 20% in foreign companies listed on a US exchange.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Pharma, Biotech & Life Sciences
Strategy
Active
Geography
--
Weighting Scheme
Proprietary
Selection Criteria
Proprietary
Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Holdings
Symbol
Ratio
Cogent Biosciences Inc
8.48%
WaVe Life Sciences Ltd
6.20%
LivaNova PLC
6.14%
Travere Therapeutics Inc
5.77%
Corcept Therapeutics Inc
5.04%
Guardant Health Inc
4.87%
Symbol
Ratio
TransMedics Group Inc
4.21%
Bridgebio Pharma Inc
4.11%
Savara Inc
4.05%
Mirum Pharmaceuticals Inc
3.89%
Top 10 Weight 52.76%
10 Total Holdings
See all holdings
Related Funds
Seasonals
Volume Profile
Trade Flow Insight
Community Forum
Loading...
Related News
No articles available
You can ask Aime
No Data
